Skip to content
Catalyst

menaquinone-7Finding

Menaquinone‑7 decreases serum undercarboxylated osteocalcin concentration

lowersVery limited evidenceFindingreplicated ×2

01 · The sentence it was drawn from

“Undercarboxylated osteocalcin decreased in the MK-7-group (- 65.2 ± 23.5%) (mean ± SD) compared with the placebo group (- 0.03 ± 38.5%), p < 0.01 after 1 year.”
Quoted verbatim from The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial.
This finding among the 4 findings on its endpoint

menaquinone-7

Serum undercarboxylated osteocalcin concentration

lowers

Who
postmenopausal women with osteopenia, both arms receiving vitamin D3 38 µg/day and calcium 800 mg/day; result at 1 year of a 3-year trial
Dose studied
MK-7 375 µg once daily, added to vitamin D3 38 µg/day and calcium 800 mg/day given to both arms

Very limited evidencePMID 33030563 · 2021

02 · The study

Study
RCT
Duration
12 months

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M7GJWT8562X4CS8XYPKBHG86